Longitudinal Early-onset Alzheimer’s Disease Study (LEADS)
What is the purpose of this study?
The purpose of this study is to observe the progression of Alzheimer's disease in participants with early onset cognitive impairment with early onset Alzheimer's disease (EOAD), early onset non-Alzheimer's disease (EO-nonAD) and cognitively normal (CN) control participants.
Who is a qualifying participant?
- Between the ages of 40 -64
- Participants can be cognitively normal (i.e., no significant memory problems), OR they can have mild cognitive impairment due to Alzheimer's disease, OR they can have mild probable Alzheimer's disease.
- Has a study partner (close friend or family member) who spends more than 10 hours per week with the participant and is willing to provide information about their thinking ability and daily functioning.
What are we asking of you in this study?
Currently, we ask for an annual visit for as long as you wish to participate or until the study closes. During your visit, we will ask for:
- Medical History: More detailed questions about your medical history, medications, family history, social history, and health habits.
- Vital Signs: Measures of blood pressure, temperature, pulse, height, weight, waist and hip circumference.
- Bloodwork: Blood is drawn to collect important health information and risk factors. (This study does not provide lab results for this bloodwork)
- Cognitive Testing: Written tests and questions will be administered by an examiner to evaluate memory and thinking.
- Neurological Evaluation: A doctor will conduct a neurological/physical exam.
- Imaging: MRI scans to measure brain structure changes over time; PET scans to look for amyloid and tau deposits (hallmarks of Alzheimer's disease).
- Cerebrospinal Fluid Collection (Optional): A lumbar puncture (LP) to measure Alzheimer’s-related proteins (amyloid and tau) may be requested but is not required for study participation. (For more information, click here)